HEALTH TECHNOLOGY

SPH Analytics Population Health Division and Azara Healthcare Announce Merger

Azara Healthcare | December 24, 2020

Azara Healthcare, a leading provider of populace health answers for the network health market, and SPH Analytics, a pioneer in healthcare shopper experience estimation, commitment and populace based analytics, today announced a merger between Azara Healthcare and SPH Analytics' populace health division. Working as Azara Healthcare, the new organization offers an exceptional blend of provider-driven populace health aptitude, information analytics, and direct availability among providers and payers. The joined association will convey profound populace health bits of knowledge to help government and business hazard contracts, quality projects, care the executives, and cost and use, while framing solid organizations among payers, providers, and individuals, to understand the guarantee of significant worth based consideration.

 

“We have spent the last decade collaborating with community health organizations who are expert population health practitioners in underserved populations, with particular emphasis on managed Medicaid,” said Jeff Brandes, who will continue serving in his role as CEO of Azara Healthcare. “As a result of this partnership, our solution is directly tied to the needs of patients and providers. With the addition of the SPH Analytics population health division, Azara now has a robust platform to extend this value to also meet the unique and growing needs of the commercial provider and payer risk markets.”

 

Presently one of the country's biggest centered populace health organizations, Azara Healthcare upholds more than 60,000 providers and payers, affecting the health of in excess of 25 million Americans. The organization's consolidated arrangements have gotten various honors and acknowledgment by noted industry investigators, for example, KLAS Research and Black Book Research.

 

With the capacity to coordinate information from different sources and help providers attach their clinical information to payer claims information, monetary frameworks, Health Information Exchanges (HIEs), and that's just the beginning, the new Azara Healthcare will currently have the option to help customers in all parts of populace health. This incorporates modified populace health activities, payer-driven worth based agreements, and state and central government announcing prerequisites, just as other doctor motivator projects, for example, the Centers for Medicare and Medicaid's Merit-based Incentive Payment System (MIPS), Accountable Care and other elective installment programs.

 

“The healthcare information technology space is complicated and often leaves providers and patients with insufficient solutions,” said Kevin Weinstein, formerly President of SPH Analytics’ population health division, now President and Chief Growth Officer of Azara Healthcare. “We have spent nearly two decades delivering strong value by enabling providers to drive behavior change with their patients, ultimately delivering better clinical outcomes and lower total cost of care. By merging with Azara, we’ve created a unique platform with enhanced data analytics, reporting, and interoperability capabilities to advance towards true accountable care models.”

 

The merger was driven by Hughes and Company, a private value firm only centered around the healthcare innovation area, with help from existing SPH Analytics financial specialist STG. SPH Analytics will stay a minority investor and a functioning colleague with Azara Healthcare.

 

“We’ve studied population health for a number of years,” said Hughes & Company Managing Director, Travis Hughes. “The promise of population health is not new—but the ability to deliver actionable benefits to patients, providers, and payers is. We see enormous potential to build upon the proven track records of Azara and SPH to create value at scale.”

 

The organization will have central command in Burlington, MA, only outside of Boston with workplaces in Alpharetta, GA, in rural Atlanta.

 

Azara Healthcare was prompted by Covington Associates and Feinberg Hanson, who filled in as speculation banking and lawful consultants, separately. Hughes and Company was spoken to by Cooley, while Paul Hastings filled in as lawful insight for SPH Analytics and STG. Terms of the exchanges were not unveiled.

 

About Azara Healthcare

Azara Healthcare is the leading provider of data-driven analytics, interoperability, quality measurement and reporting for the Community Health and physician practice market. Azara solutions empower more than 1,000 Community Health Centers, physician practices, Primary Care Associations, Health Center Controlled Networks, clinically integrated networks and regional health plans in 36 states to improve the quality and efficiency of care for more than 25 million Americans through actionable data. Azara consistently earns accolades as a top population health vendor by industry market intelligence firm KLAS Research and was ranked number one in MACRA and MIPS Support Technology for Value-Based Care by Black Book Research.

Spotlight

It’s a critically important day because more than 500 million people, many unknowingly, are affected by viral hepatitis globally. And more so for us here in Asia Pacific where recent data showed that 70% of the 1.4 million annual global deaths associated with the disease occur. hepatitis.


Other News
FUTURE OF HEALTHCARE

Kubat HealthCare acquires Hilltop Drugs Etc

Kubat Healthcare | May 10, 2022

Kubat HealthCare, a leading health care service provider, announces today the acquisition of Hilltop Drugs Etc located at 108 W 11th St in Neligh, Nebraska 68756. Founded in October 2008 by co-founder and current Pharmacist-In-Charge, Jami Schmidt, Hilltop Drugs Etc quickly became a community staple providing personalized pharmacy and healthcare services. In 2019, Jami Schmidt and her business partner sold to Mark Vogt. "When I started Hilltop Drugs Etc in 2008, I wanted to provide the community with exceptional pharmacy solutions," said Jami Schmidt, who will remain as the Pharmacist-In-Charge, "I am thrilled that by joining with Kubat HealthCare, not only will our community continue to have pharmacy needs met, but we will now be able to offer additional health care services that have not been made available until now." By joining the Kubat HealthCare family, Neligh and surrounding communities will benefit from the access to respiratory care, specialized compounded medications, infusion, and home medical equipment solutions through their other locations in Nebraska. Hilltop Drugs Etc will continue to offer home delivery and mailing of patient's prescriptions, RediMedi compliance packaging, vaccinations, and assistance with enrolling in Medicare Part D prescription insurance plans. "The team at Hilltop Drugs is exceptional. While the name will change in the coming months, we are ecstatic to have Jami Schmidt and the team continue to provide exceptional service to the community." Tony Schmid, Vice President of Pharmacy Operations at Kubat HealthCare At Kubat HealthCare, their growth initiative has been focused on entering communities that have been previously underserved by their healthcare options. "Through our network, our team members are able to provide additional healthcare services to communities throughout the Midwest" said Bret Cain, COO of Kubat HealthCare, "And as we continue to grow, it reassures me that we are creating a beneficial healthcare network of service offerings to deserving communities."

Read More

FUTURE OF HEALTHCARE

Aatru Medical, LLC Completes Acquisition of Key Supplier Exothermix

Aatru Medical | April 28, 2022

Aatru Medical is pleased to announce the acquisition of Exothermix, the inventor and supplier of the unique mode-of-action component in the NPSIMSTM incisional management negative pressure system. Exothermix is an innovation company with patented technology and manufacturing of simple, fast, and safe oxygen scavengers with various uses including on-demand self-heating solutions that serve the medical, military, beauty, and personal care markets with these customized products. “We are very pleased to join the Aatru family. The resulting synergies allow us to not only continue to be a key component supplier to Aatru Medical, but this also allows us to continue to develop and to manufacturer industry-changing products for our existing and future customers.” Daniel Hancock, who will remain as President of Exothermix The full Exothermix management and staff will remain in place in the College Station, TX facility and continue to service existing customers. Aatru Medical President Edward Armstrong noted, “The acquisition brings together two innovative technologies and business cultures, which provides a stronger platform for future growth, through accelerated product development and the seamless integration of our supply chain.” Aatru Medical, LLC is a privately-owned medical device company located in Cleveland, OH. The company’s recently FDA-cleared NPSIMSTM is a pre-assembled, single use solid-state negative pressure system for surgical incision management.

Read More

MEDICAL DEVICES

BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing

BD | December 22, 2021

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medical tests.BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor™ At-Home COVID-19 Test, the first at-home COVID-19 test that uniquely uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases including COVID-19/influenza A+B, group A strep and additional menu for detecting infections and managing chronic disease. "The COVID-19 pandemic has accelerated the shift to new care settings, and BD is ready to deliver a smart, connected at-home diagnostic ecosystem to support traditional and telehealth providers and consumers. This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future." Dave Hickey, president of Life Sciences for BD The Scanwell app is a key differentiator in the market for at-home COVID-19 testing. To date, no other company uses the phone's camera to capture the image of the test that is then analyzed and interpreted by the app. Other COVID-19 home tests use smartphones as part of their process, but BD Veritor™ At-Home COVID-19 Test is the first and only test to use the smartphone as the analyzer to digitally interpret the test results and provide a definitive POSITIVE or NEGATIVE digital display of testing results. The app also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app. Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Scanwell financial results will be reported under the Integrated Diagnostic Solutions business within the Life Sciences segment. About the BD Veritor™ At-Home COVID-19 Test The BD Veritor™ At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

FUTURE OF HEALTHCARE

WELL Health Enters into Automatic Share Purchase Plan

WELL Health Technologies Corp. | June 16, 2022

WELL Health Technologies Corp.ca company focused on positively impacting health outcomes by leveraging technology to empower practitioners and their patients globally, announced today that it has entered into an automatic share purchase plancwith a broker in order to facilitate repurchases of the Company's common shares under its previously announced normal course issuer bid. WELL previously announced that it had received approval from the Toronto Stock Exchange to, during the 12-month period commencing June 1, 2022 and terminating May 31, 2023, purchase up to 5,555,386 Common Shares, representing approximately 2.5% of the 222,215,443 Common Shares issued and outstanding as of May 30, 2022, by way of a NCIB on the TSX or through alternative trading systems or by such other means as may be permitted under applicable law. During the effective period of WELL's ASPP, WELL's broker may purchase Common Shares at times when WELL would not be active in the market due to insider trading rules and its own internal trading blackout periods. Purchases will be made by WELL's broker based upon parameters set by WELL when it is not in possession of any undisclosed material information about itself and its securities, and in accordance with the terms of the ASPP. Outside of the effective period of the ASPP, Common Shares may continue to be purchased in accordance with WELL's discretion, subject to applicable law. The ASPP has been entered into in accordance with the requirements of applicable Canadian securities laws. About WELL Health Technologies Corp. WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multinational, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and is part of the TSX Composite Index. The Company also trades on the OTCQX Markets under the symbol "WHTCF".

Read More

Spotlight

It’s a critically important day because more than 500 million people, many unknowingly, are affected by viral hepatitis globally. And more so for us here in Asia Pacific where recent data showed that 70% of the 1.4 million annual global deaths associated with the disease occur. hepatitis.

Resources